Clinical and immunological features of severe and moderate coronavirus disease 2019

Chen, Guang; Wu, Di; Guo, Wei; Cao, Yong; Huang, Da; Wang, Hongwu; Wang, Tao; Zhang, Xiaoyun; Chen, Huilong; Yu, Haijing; Zhang, Xiaoping; Zhang, Minxia; Wu, Shiji; Song, Jin Yeong; Chen, Tao; Han, Meifang; Li, Shusheng; Luo, Xiaoping; Zhao, Jianping; Ning, Qin

doi:10.1172/jci137244

Cited by 4,180 publications

(4,882 citation statements)

References 22 publications

Supporting

309

Mentioning

4,397

Contrasting

Unclassified

121

Order By: Relevance

“…In SARS-CoV-2 patients with a worse prognosis, IL-6, IL-10, and TNF-α quickly rise and reach high levels. Conversely, in patients with milder symptoms, these cytokines reach lower levels, with their expression rising and declining during the illness and recovery phase, respectively [33].…”

Section: Sars-cov-2 Infection and The Pathophysiology Of Cytokine Relmentioning

confidence: 99%

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity

Picchianti-Diamanti

Rosado

Pioli

et al. 2020

IJMS

100

View full text Add to dashboard Cite

On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency. Typical manifestations consist of flu-like symptoms such as fever, cough, fatigue, and dyspnea. However, in about 20% of patients, the infection progresses to severe interstitial pneumonia and can induce an uncontrolled host-immune response, leading to a life-threatening condition called cytokine release syndrome (CRS). CRS represents an emergency scenario of a frequent challenge, which is the complex and interwoven link between infections and autoimmunity. Indeed, treatment of CRS involves the use of both antivirals to control the underlying infection and immunosuppressive agents to dampen the aberrant pro-inflammatory response of the host. Several trials, evaluating the safety and effectiveness of immunosuppressants commonly used in rheumatic diseases, are ongoing in patients with COVID-19 and CRS, some of which are achieving promising results. However, such a use should follow a multidisciplinary approach, be accompanied by close monitoring, be tailored to patient's clinical and serological features, and be initiated at the right time to reach the best results. Autoimmune patients receiving immunosuppressants could be prone to SARS-CoV-2 infections; however, suspension of the ongoing therapy is contraindicated to avoid disease flares and a consequent increase in the infection risk.

show abstract

Section: Sars-cov-2 Infection and The Pathophysiology Of Cytokine Relmentioning

confidence: 99%

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity

Picchianti-Diamanti

Rosado

Pioli

et al. 2020

IJMS

100

View full text Add to dashboard Cite

show abstract

“…En el momento de redactar este artículo, existen pocas publicaciones que aborden la dinámica de la tormenta de citoquinas en la infección por SARS-CoV2. Muy recientemente, Chen et al presentaron un estudio en el que demuestran que la infección por SARS-CoV2 severa se asocia con linfopenia a expensas de caídas de Linfocitos T CD4+ y CD8+ pero no de Linfocitos B, hiperproducción de Citoquinas IL6, IL2R (receptor soluble de la IL2), IL10, TNFα y CCL2 y descenso en la expresión de IFN-γ en linfocitos T CD4+ [15]. Los niveles de IL6, IL2R, IL10 y TNFα suben discretamente o permanecen en rango normal en casos moderados pero muy elevados en casos severos (ver Figura 1).…”

Section: Fases De La Expresión Clínica De Las Infecciones Por Covunclassified

Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?

et al. 2020

View full text Add to dashboard Cite

INTRODUCCIÓN: La infección por el coronavirus SARS-CoV2 originada en Diciembre de 2019 en la región china de Wuhan ha adquirido proporciones pandémicas. A día de hoy ha ocasionado de Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic?ABSTRACT Introduction: SARS-CoV-2 was first detected in December 2019 in the Chinese city of Wuhan and has since spread across the world. At present, the virus has infected over 1.7 million people and caused over 100 000 deaths worldwide. Research is currently focused on understanding the acute infection and developing effective treatment strategies. In view of the magnitude of the epidemic, we conducted a speculative review of possible medium-and long-term neurological consequences of SARS-CoV-2 infection, with particular emphasis on neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin, based on the available evidence on neurological symptoms of acute SARS-CoV-2 infection. Development:We systematically reviewed the available evidence about the pathogenic mechanisms of SARS-CoV-2 infection, the immediate and lasting effects of the cytokine storm on the central nervous system, and the consequences of neuroinflammation for the central nervous system.Conclusions: SARS-CoV-2 is a neuroinvasive virus capable of triggering a cytokine storm, with persistent effects in specific populations. Although our hypothesis is highly speculative, the impact of SARS-CoV-2 infection on the onset and progression of neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin should be regarded as the potential cause of a delayed pandemic that may have a major public health impact in the medium to long term. Cognitive and neuropsychological function should be closely monitored in COVID-19 survivors.

show abstract

“…Desde la aparición en Diciembre de 2019 de los primeros casos de infección por el Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) en la provincia china de Hubei, la infección causada por este patógeno se ha extendido a nivel mundial con un alto índice de infectividad y tasas de letalidad nada desdeñables. El cuadro típico asociado a la infección por SARS-CoV2 incluye fiebre, astenia y tos seca (1) con un cuadro de insuficiencia respiratoria en los pacientes más graves con daño alveolar secundario a una liberación masiva de moléculas proinflamatorias (2). Sin embargo, poco sabemos de las complicaciones neurológicas asociadas a la infección por SARS-CoV2 (3).…”

Section: Síndrome De Guillain-barré Fatal Tras Infección Por Virus Saunclassified

Síndrome de Guillain-Barré fatal tras infección por el virus SARS-CoV-2

2020

View full text Add to dashboard Cite

Clinical and immunological features of severe and moderate coronavirus disease 2019

Cited by 4,180 publications

References 22 publications

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity

Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?

Síndrome de Guillain-Barré fatal tras infección por el virus SARS-CoV-2

Contact Info

Product

Resources

About